PRESS RELEASE, 5 November 2019

/in /by

Iconovo and CrystecPharma to collaborate in development of innovative inhaler products

Iconovo today announced that it signed a Letter of Understanding with CrystecPharma to collaborate in the development of innovative dry powder inhaler (DPI) products.

The two companies have complementary expertise that will allow them to develop mSAS® (modified supercritical anti-solvent) engineered particles for delivery to the lung using an inhaler from Iconovo. Many compounds cannot be formulated with traditional micronised or spray dried carrier-based inhalation powder formulations. This particularly applies to compounds which are poorly stable, sensitive to heat or moisture, or to fragile macromolecules. Read more